The clinical case for proton beam therapy

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Foote, Robert L ^a   Stafford, Scott L ^a   Petersen, Ivy A ^a   Pulido, Jose S ^a   Clarke, Michelle J ^a   Schild, Steven E ^c   Garces, Yolanda I ^a   Olivier, Kenneth R ^a   Miller, Robert C ^a   Haddock, Michael G ^a   Yan, Elizabeth ^a   Laack, Nadia N ^a   Arndt, Carola A S ^a   Buskirk, Steven J ^d   Miller, Vickie L ^a   Brent, Christopher R ^a   Kruse, Jon J ^a   Ezzell, Gary A ^c   Herman, Michael G ^a   Gunderson, Leonard L ^a   Erlichman, Charles ^a   Diasio, Robert B ^a,b   more..

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Clinical review; Neoplasms; Proton beam therapy; X ray therapy

Indexed keywords

BLADDER CANCER; BREAST CANCER; CANCER CONTROL; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHILDHOOD CANCER; CHORDOMA; ENUCLEATION; ESOPHAGUS CANCER; EYE CANCER; HEAD AND NECK CANCER; HEART CANCER; HELIUM ION RADIATION; HODGKIN DISEASE; HUMAN; INTESTINE CANCER; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; OSTEOSARCOMA; PANCREAS CANCER; PROSTATE CANCER; PROTON THERAPY; RADIATION DOSE; RADIOSURGERY; REVIEW; SKULL BASE CHORDOMA; SPINAL CORD CANCER; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; NEOPLASMS;

PROTON;

HUMANS; NEOPLASMS; PROTON THERAPY; PROTONS;

EID: 84867660663     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-174     Document Type: Review

References (70)

1. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S3-S9. 3431964, 20171515.
2. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, et al. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings: COMS Report No. 18. Arch Ophthalmol 2001, 119(7):969-982.
3. Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma: a prospective, randomized, dynamically balanced trial. Ophthalmology 1993, 100(10):1547-1554.
4. Jensen AW, Petersen IA, Kline RW, Stafford SL, Schomberg PJ, Robertson DM. Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int J Radiat Oncol Biol Phys 2005, 63(1):101-108. 10.1016/j.ijrobp.2005.01.022, 16111577.
5. Rajendran RR, Weinberg V, Daftari IK, Castro JR, Quivey JM, Char DH, et al. Decreased incidence of neovascular glaucoma by sparing anterior structures of the eye for proton beam therapy of ocular melanoma [abstract]. Int J Radiat Oncol Biol Phys 2004, 60(1):S311-S312.
6. Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys 2005, 62(5):1405-1411. 10.1016/j.ijrobp.2005.01.016, 16029800.
7. Munzenrider JE. Uveal melanomas: conservation treatment. Hematol Oncol Clin North Am 2001, 15(2):389-402. 10.1016/S0889-8588(05)70219-7, 11370500.
8. Dendale R, Lumbroso-Le Rouic L, Noel G, Feuvret L, Levy C, Delacroix S, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys 2006, 65(3):780-787. Epub 2006 May 2., 10.1016/j.ijrobp.2006.01.020, 16647221.
9. Egger E, Schalenbourg A, Zografos L, Bercher L, Boehringer T, Chamot L, et al. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys 2001, 51(1):138-147. 10.1016/S0360-3016(01)01560-7, 11516863.
10. Gragoudas ES, Lane AM, Regan S, Li W, Judge HE, Munzenrider JE, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol 2000, 118(6):773-778.
11. Krishnan S, Foote RL, Brown PD, Pollock BE, Link MJ, Garces YI. Radiosurgery for cranial base chordomas and chondrosarcomas. Neurosurgery 2005, 56(4):777-784. discussion 777-84., 10.1227/01.NEU.0000156789.10394.F5, 15792516.
12. Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys 2009, 75(4):1111-1118. Epub 2009 Apr 20., 10.1016/j.ijrobp.2008.12.055, 19386442.
13. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol 1999, 175(Suppl 2):57-63.
14. Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103(19):1452-1460. Epub 2011 Sep 8. Erratum in: J Natl Cancer Inst. 2012 Jan 4;104[1]:79., 10.1093/jnci/djr325, 3186782, 21903745.
15. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004, 46(1):87-98. 10.1016/j.lungcan.2004.03.004, 15364136.
16. Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 65(4):1106-1111. Epub 2006 May 26., 10.1016/j.ijrobp.2006.02.046, 16730134.
17. Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, et al. Early Findings on Toxicity of Proton Beam Therapy with Concurrent Chemotherapy in Nonsmall Cell Lung Cancer. Cancer 2011, 117:3004-3013. 10.1002/cncr.25848, 21264827.
18. Bradley JD, Paulus R, Komaki R, Masters G, Forster K, Schild SE, et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy +/- cetuximab for stage IIIA/IIIB non-small cell lung cancer: preliminary findings on radiation dose in RTOG 0617 [abstract] 2011, Miami Beach, FL: 53rd Annual Meeting of the American Society for Radiation Oncology.
19. Cox JD. Are the results of RTOG 0617 mysterious?. Int J Radiat Oncol Biol Phys 2012, 82(3):1042-1044. 10.1016/j.ijrobp.2011.12.032, 22284026.
20. Chung CS, Keating N, Yock T, Tarbell N. Comparative analysis of second malignancy risk in patients treated with proton therapy versus conventional photon therapy [abstract]. Int J Radiat Oncol Biol Phys 2008, 72(1):S8.
21. Schneider U, Lomax A, Pemler P, Besserer J, Ross D, Lombriser N, et al. The impact of IMRT and proton radiotherapy on secondary cancer incidence. Strahlenther Onkol 2006, 182(11):647-652. 10.1007/s00066-006-1534-8, 17072522.
22. Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007, 25(1):43-49. Erratum in: J Clin Oncol. 2007 Apr 20;25[12]:1635..
23. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003, 290(21):2831-2837. 10.1001/jama.290.21.2831, 14657067.
24. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, et al. Radiation Therapy Oncology Group. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999, 281(17):1623-1627. 10.1001/jama.281.17.1623, 10235156.
25. Gayed IW, Liu HH, Yusuf SW, Komaki R, Wei X, Wang X, et al. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med 2006, 47(11):1756-1762.
26. Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009, 27(14):2328-2338. Epub 2009 Mar 30., 10.1200/JCO.2008.21.1425, 2677921, 19332714.
27. Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL, et al. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst 2010, 102(16):1272-1283. Epub 2010 Jul 23., 10.1093/jnci/djq278, 2948841, 20656964.
28. Aksnes LH, Bauer HC, Dahl AA, Fossa SD, Hjorth L, Jebsen N, et al. Health status at long-term follow-up in patients treated for extremity localized Ewing Sarcoma or osteosarcoma: a Scandinavian sarcoma group study. Pediatr Blood Cancer 2009, 53(1):84-89. 10.1002/pbc.22027, 19343771.
29. Punyko JA, Mertens AC, Gurney JG, Yasui Y, Donaldson SS, Rodeberg DA, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. Pediatr Blood Cancer 2005, 44(7):643-653. 10.1002/pbc.20310, 15700252.
30. Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010, 102(14):1083-1095. Epub 2010 Jul 15., 10.1093/jnci/djq238, 2907408, 20634481.
31. Navid F, Billups C, Liu T, Krasin MJ, Rodriguez-Galindo C. Second cancers in patients with the Ewing sarcoma family of tumours. Eur J Cancer 2008, 44(7):983-991. Epub 2008 Mar 18., 10.1016/j.ejca.2008.02.027, 2423466, 18353632.
32. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res 2010, 174(6):840-850. Epub 2010 Sep 17., 10.1667/RR1903.1, 3080029, 21128808.
33. Miralbell R, Lomax A, Bortfeld T, Rouzaud MM, Carrie C. Potential role of proton therapy in the treatment of pediatric edulloblastoma/primitive neuroectodermal tumors: reduction of the supratentorial target volume. Int J Radiat Oncol Biol Phys 1997, 38(3):477-484. 10.1016/S0360-3016(97)00004-7, 9231669.
34. Grill J, Renaux VK, Bulteau C, Viguier D, Levy-Piebois C, Sainte-Rose C, et al. Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys 1999, 45(1):137-145. 10.1016/S0360-3016(99)00177-7, 10477017.
35. Mulhern RK, Kepner JL, Thomas PR, Armstrong FD, Friedman HS, Kun LE. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol 1998, 16(5):1723-1728.
36. Taylor RE, . United Kingdom Children's Cancer Study Group Morbidity from abdominal radiotherapy in the First United Kingdom Children's Cancer Study Group Wilms' Tumour Study. Clin Oncol (R Coll Radiol) 1997, 9(6):381-384. United Kingdom Children's Cancer Study Group.
37. Willman KY, Cox RS, Donaldson SS. Radiation induced height impairment in pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys 1994, 28(1):85-92. 10.1016/0360-3016(94)90144-9, 8270462.
38. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 2002, 54(3):824-829. 10.1016/S0360-3016(02)02982-6, 12377335.
39. Mu X, Bjork-Eriksson T, Nill S, Oelfke U, Johansson KA, Gagliardi G, et al. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? a comparative treatment planning study. Acta Oncol 2005, 44(6):554-562. 10.1080/02841860500218819, 16165914.
40. St Clair WH, Adams JA, Bues M, Fullerton BC, La Shell S, Kooy HM, et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004, 58(3):727-734. 10.1016/S0360-3016(03)01574-8, 14967427.
41. Lundkvist J, Ekman M, Ericsson SR, Jonsson B, Glimelius B. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer 2005, 103(4):793-801. 10.1002/cncr.20844, 15637691.
42. Lee CT, Bilton SD, Famiglietti RM, Riley BA, Mahajan A, Chang EL, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques?. Int J Radiat Oncol Biol Phys 2005, 63(2):362-372. 10.1016/j.ijrobp.2005.01.060, 16168831.
43. Yock T, Schneider R, Friedmann A, Adams J, Fullerton B, Tarbell N. Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys 2005, 63(4):1161-1168. Epub 2005 Jun 13., 10.1016/j.ijrobp.2005.03.052, 15950401.
44. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366(9503):2087-2106.
45. Lomax AJ, Cella L, Weber D, Kurtz JM, Miralbell R. Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes. Int J Radiat Oncol Biol Phys 2003, 55(3):785-792. 10.1016/S0360-3016(02)04210-4, 12573766.
46. Johansson J, Isacsson U, Lindman H, Montelius A, Glimelius B. Node-positive left-sided breast cancer patients after breast-conserving surgery: potential outcomes of radiotherapy modalities and techniques. Radiother Oncol 2002, 65(2):89-98. 10.1016/S0167-8140(02)00266-9, 12443804.
47. Weber DC, Ares C, Lomax AJ, Kurtz JM. Radiation therapy planning with photons and protons for early and advanced breast cancer: an overview. Radiat Oncol 2006, 1:22. 10.1186/1748-717X-1-22, 1553457, 16857055.
48. Taghian AG, Kozak KR, Katz A, Adams J, Lu HM, Powell SN, et al. Accelerated partial breast irradiation using proton beams: initial dosimetric experience. Int J Radiat Oncol Biol Phys 2006, 65(5):1404-1410. Epub 2006 May 26., 10.1016/j.ijrobp.2006.03.017, 16730137.
49. Kozak KR, Katz A, Adams J, Crowley EM, Nyamwanda JA, Feng JK, et al. Dosimetric comparison of proton and photon three-dimensional, conformal, external beam accelerated partial breast irradiation techniques. Int J Radiat Oncol Biol Phys 2006, 65(5):1572-1578. 10.1016/j.ijrobp.2006.04.025, 16863934.
50. Lundkvist J, Ekman M, Ericsson SR, Isacsson U, Jonsson B, Glimelius B. Economic evaluation of proton radiation therapy in the treatment of breast cancer. Radiother Oncol 2005, 75(2):179-185. 10.1016/j.radonc.2005.03.006, 15885828.
51. Kozak KR, Smith BL, Adams J, Kornmehl E, Katz A, Gadd M, et al. Accelerated partial-breast irradiation using proton beams: initial clinical experience. Int J Radiat Oncol Biol Phys 2006, 66(3):691-698. 10.1016/j.ijrobp.2006.06.041, 17011445.
52. Bush DA, Slater JD, Garberoglio C, Yuh G, Hocko JM, Slater JM. A technique of partial breast irradiation utilizing proton beam radiotherapy: comparison with conformal x-ray therapy. Cancer J 2007, 13(2):114-118. 10.1097/PPO.0b013e318046354b, 17476139.
53. Bush DA, Slater JD, Garberoglio C, Do S, Lum S, Slater JM. Partial breast irradiation delivered with proton beam: results of a phase II trial. Clin Breast Cancer 2011, 11(4):241-245. Epub 2011 Jun 12., 10.1016/j.clbc.2011.03.023, 21729673.
54. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999, 353(9149):267-272. 10.1016/S0140-6736(98)05180-0, 9929018.
55. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000, 48(3):635-642. 10.1016/S0360-3016(00)00700-8, 11020558.
56. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000, 18(23):3904-3911.
57. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24(13):1990-1996. 10.1200/JCO.2005.05.2530, 16648499.
58. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006, 176(4 Pt 1):1415-1419.
59. Slater JD, Rossi CJ, Yonemoto LT, Bush DA, Jabola BR, Levy RP, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 2004, 59(2):348-352. 10.1016/j.ijrobp.2003.10.011, 15145147.
60. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294(10):1233-1239. Erratum in: JAMA. 2008 Feb 27;299[8]:899-900., 10.1001/jama.294.10.1233, 16160131.
61. Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 2010, 303(11):1046-1053. Erratum in: JAMA. 2010 Apr 7;303[13]:1257., 10.1001/jama.2010.287, 20233822.
62. Konski A, Speier W, Hanlon A, Beck JR, Pollack A. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol 2007, 25(24):3603-3608. 10.1200/JCO.2006.09.0811, 17704408.
63. King CR, Brooks JD, Gill H, Presti JC. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82(2):877-882. Epub 2011 Feb 6., 10.1016/j.ijrobp.2010.11.054, 21300474.
64. Van de Water TA, Lomax AJ, Bijl HP, De Jong ME, Schilstra C, Hug EB, et al. Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2011, 79(4):1216-1224. Epub 2010 Aug 21., 10.1016/j.ijrobp.2010.05.012, 20732761.
65. Slater JD, Yonemoto LT, Mantik DW, Bush DA, Preston W, Grove RI, et al. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. Int J Radiat Oncol Biol Phys 2005, 62(2):494-500. 10.1016/j.ijrobp.2004.09.064, 15890592.
66. Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, Mcintyre J, Adams J, et al. Neuroendocrine tumors of the sinonasal tract: results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 2002, 94(10):2623-2634. 10.1002/cncr.10537, 12173330.
67. Truong MT, Kamat UR, Liebsch NJ, Curry WT, Lin DT, Barker FG, et al. Proton radiation therapy for primary sphenoid sinus malignancies: treatment outcome and prognostic factors. Head Neck 2009, 31(10):1297-1308. 10.1002/hed.21092, 19536762.
68. Lee IJ, Koom WS, Lee CG, Kim YB, Yoo SW, Keum KC, et al. Risk factors and dose-effect relationship for mandibular osteoradionecrosis in oral and oropharyngeal cancer patients. Int J Radiat Oncol Biol Phys 2009, 75(4):1084-1091. Epub 2009 Mar 26., 10.1016/j.ijrobp.2008.12.052, 19327914.
69. Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S58-S63.
70. Luce BR, Brown RE. The use of technology assessment by hospitals, health maintenance organizations, and third-party payers in the United States. Int J Technol Assess Health Care 1995, 11(1):79-92. 10.1017/S0266462300005274, 7706016.